Immunocore Holdings PLC
IMCRHealthcare|Biotechnology|UK
$31.95
-1.18 (-3.56%)
Tangible Book
$7.75
About
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Stock Price
-9.9%(1Y)
Pipeline Summary
20 total trials10
Phase 1
12
Phase 2
3
Phase 3
0
Phase 4
Recruiting: 8NOT_YET_RECRUITING: 1Active: 2Completed: 3Withdrawn: 3AVAILABLE: 1Terminated: 2
Active Trials (10)
Neoadjuvant Tebentafusp for Uveal Melanoma
NCT06414590Locally Advanced Unresectable Uveal Melanoma
Phase 2Recruiting
Enrollment: 19 participants
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
Phase 3Recruiting
Enrollment: 540 participants
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
NCT06070012Uveal Melanoma
Phase 2Recruiting
Enrollment: 44 participants
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT06246149Uveal Melanoma
Phase 3Recruiting
Enrollment: 290 participants
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466Select Advanced Solid Tumors
Phase 1Phase 2Active
Enrollment: 410 participants
BioScore
6.4/10
Watchlist
Ownership
Recent Insider Trades
Jallal BahijaSELL
2026-02-1811,474 shares @ $32.35
GOLL JOHNSELL
2026-02-18698 shares @ $32.35
St Leger Tina AmberSELL
2026-02-181,000 shares @ $32.35
Berman David MSELL
2026-02-185,965 shares @ $32.35
Berman David MSELL
2025-12-0531,913 shares @ $40.26
Data last updated: Jul 12, 2026, 07:39 PM